Navigation Links
Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
Date:5/12/2009

ns and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of operations, liquidity and capital resources, financial prospects, business objectives and strategic goals, drug development plans and commercialization strategy, the timing and results of clinical trials and the potential safety and efficacy of the Company's products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market; the Company's research and development activities; the results of preclinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company'
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Independent ... County), California, and Montreal, Canada, has big ideas for ... non-fiction. The press's goals are to produce high-quality, low-cost, ... to support local businesses. , The first major ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... market and business intelligence company, the vaccine market is a huge and ... of about 15 to 18%. The vaccine market could account for more ... ... 2009 -- Vaccines are substances used to stimulate the production of antibodies ...
... (NYSE: BEC ), a leading developer, manufacturer, ... complex biomedical testing, will webcast its Annual Stockholders, Meeting ... (ET). The webcast may be accessed by visiting ... access the webcast select "go to IR" under Investor ...
... estimate the origin and time of an aerosolized release ... first few cases has been developed by researchers from ... and Modelling at Imperial College London in collaboration with ... , The method, described in an article published April ...
Cached Biology Technology:CBDM.T, The Market and Business Intelligence Company Reviews The Vaccine Market 2CBDM.T, The Market and Business Intelligence Company Reviews The Vaccine Market 3Novel method predicts impact of a covert anthrax release 2
(Date:7/9/2014)... of Guelph scientist that involved fitting bumblebees with ... a neonicotinoid pesticide hampers bees, ability to forage ... a professor in Guelph,s School of Environmental Sciences, ... published July 9 in the British Ecological Society,s ... shows how long-term pesticide exposure affects individual bees, ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
Breaking Biology News(10 mins):Bee foraging chronically impaired by pesticide exposure: Study 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... bird nests don,t survive due to predators, particularly in fragmented ... both the prey and predator to find an answer. ... cases of nest predation," said U of I researcher Patrick ... much more time on the edges of the forest, that,s ...
... , URBANA In the race to find answers about ... five years, University of Illinois researchers have been using the ... have recently discovered that a diet enriched with flaxseed decreases ... Flaxseed is the richest plant source of alpha-linolenic acid, ...
... disease is a rare but serious infection resulting from ... Approximately 250 people have been infected with the disease in ... cause meningitis, pneumonia and in 10 per cent of cases ... how the fungus leaves the bloodstream and enters the brain; ...
Cached Biology News:Fragmented forests result in more snakes, fewer birds 2Fragmented forests result in more snakes, fewer birds 3Flaxseed-fed chickens shed light on ovarian cancer 2Flaxseed-fed chickens shed light on ovarian cancer 3Vancouver Island has one of the highest rates of Cryptococcus infection in the world 2
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
B-FABP (FL-132)...
... Recombinant Enterokinase (rEK) is a highly purified ... enterokinase, a serine protease which recognizes the ... (AspAspAspAspLys?) and has similar enzymatic activity (1). ... and purified to yield the highest activity ...
Strip Removal Tool 25/Box...
Biology Products: